These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 21222326)
21. Neurohormones and heart failure: the importance of aldosterone. Odedra K; Ferro A Int J Clin Pract; 2006 Jul; 60(7):835-46. PubMed ID: 16846401 [TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin and cardiovascular continuum when time is important. Barrios V; Escobar C J Am Coll Cardiol; 2010 Apr; 55(15):1645-6; author reply 1646. PubMed ID: 20378088 [No Abstract] [Full Text] [Related]
23. What's old is new again. Spironolactone and heart failure. Lock M; Chun R Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769 [No Abstract] [Full Text] [Related]
24. [Therapy of chronic heart failure with beta-receptor blockers]. Böhm M Z Kardiol; 1996; 85 Suppl 7():11-21. PubMed ID: 9082679 [TBL] [Abstract][Full Text] [Related]
25. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]. Diercks GF; Overdiek JW; van Veldhuisen DJ Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145 [TBL] [Abstract][Full Text] [Related]
26. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309 [TBL] [Abstract][Full Text] [Related]
27. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692 [TBL] [Abstract][Full Text] [Related]
32. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243 [TBL] [Abstract][Full Text] [Related]
33. Experience with beta blockers in heart failure mortality trials. Eichhorn EJ Clin Cardiol; 1999 Oct; 22 Suppl 5():V21-9. PubMed ID: 10526700 [TBL] [Abstract][Full Text] [Related]
34. Reply to Letter From Floras et al.--Central Sleep Apnea: Risk Factor or Pathogenic Process in Patients With Heart Failure. Yogasundaram H; Oudit GY Can J Cardiol; 2016 Mar; 32(3):396.e5. PubMed ID: 26831512 [No Abstract] [Full Text] [Related]
35. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. Butler J; Anstrom KJ; Armstrong PW Circulation; 2020 Aug; 142(8):717-719. PubMed ID: 32223438 [No Abstract] [Full Text] [Related]
36. New trials of gene therapy for heart failure are announced. Watts G BMJ; 2013 Apr; 346():f2795. PubMed ID: 23633009 [No Abstract] [Full Text] [Related]
37. Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure. Pitt B Eur Heart J; 2020 May; 41(17):1615-1617. PubMed ID: 32357236 [No Abstract] [Full Text] [Related]
38. Figures of the Heart Failure Association: Professor Dr. med. Johann Bauersachs, Chair of the Clinical Science Section. Coats AJS Eur J Heart Fail; 2019 May; 21(5):545-548. PubMed ID: 31069912 [No Abstract] [Full Text] [Related]
39. Correspondence (letter to the editor): Important study should have been considered. Middeke M; Kottmair S Dtsch Arztebl Int; 2010 Sep; 107(36):630; author reply 630. PubMed ID: 20948780 [No Abstract] [Full Text] [Related]
40. Professor Dirk Hellhammer (1947-2018): 45 years of influential psychoneuroendocrinology research. Kirschbaum C Psychoneuroendocrinology; 2018 Dec; ():. PubMed ID: 30579646 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]